Enrique Grande: FGFR inhibitors shaping the future of precision medicine
Enrique Grande, the Head of Oncology at MD Anderson Cancer Center Madrid, posted the following on LinkedIn:
“FGFR inhibitors are shaping the future of precision medicine in urothelial carcinoma. Recent advancements, including erdafitinib’s FDA approval and promising combination regimens, highlight their growing role in targeted therapy for biomarker-selected patients. Expanding their use to earlier stages of disease remains a key challenge.”
Expanding the Reach of FGFR Inhibitors to Advance Precision Medicine in Urothelial Carcinoma
Authors: Vadim S. Koshkin, Guru P. Sonpavde.
More posts featuring Enrique Grande.
Enrique Grande, MD, PhD, MSc, is the Head of Oncology at MD Anderson Cancer Center Madrid, and an Associate Professor at Francisco de Vitoria University. He is also an Adjunct Professor at the GU Medical Oncology Department.
Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit.
He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE).
Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023